Pekin Hardy Strauss Inc. Invests $225,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Pekin Hardy Strauss Inc. bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 2,050 shares of the medical equipment provider’s stock, valued at approximately $225,000.

Other large investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in shares of Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 208 shares during the last quarter. Signaturefd LLC boosted its stake in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares during the last quarter. Nkcfo LLC purchased a new position in Lantheus during the 2nd quarter valued at approximately $47,000. UMB Bank n.a. increased its stake in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 126 shares during the last quarter. Finally, Kathleen S. Wright Associates Inc. purchased a new stake in shares of Lantheus during the 3rd quarter worth approximately $51,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Price Performance

LNTH stock opened at $90.96 on Tuesday. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The firm’s 50-day moving average is $103.13 and its 200 day moving average is $96.93. The company has a market capitalization of $6.32 billion, a PE ratio of 15.13 and a beta of 0.51.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on LNTH. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Truist Financial restated a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Redburn Atlantic initiated coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target for the company. Finally, JMP Securities lowered their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $122.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.